SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression
Oisun Jung(University of Nebraska Medical Center), Alan C. Rapraeger(University of Wisconsin–Madison)
Cited by 0
Related Papers
Syndecan-1 regulates αvβ3 and αvβ5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor
|The Journal of Experimental Medicine|2009|278
Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
|Oncogenesis|2016|111
Interaction of Syndecan and α6β4 Integrin Cytoplasmic Domains
|Journal of Biological Chemistry|2010|67
Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer
|The EMBO Journal|2024|28